Biocon Limited FII & DII Activity
5-Day Flow Trend
| Date | FII Net (₹ Cr) | DII Net (₹ Cr) |
|---|---|---|
| 2026-10-28 | +871.83 | +643.35 |
| 2026-10-27 | −1462.49 | +2609.57 |
| 2026-10-26 | −1462.49 | +2609.57 |
| 2026-10-23 | +887.65 | +3235.36 |
| 2026-10-22 | −3458.70 | +2891.32 |
Today's Institutional Flow
Foreign Institutional Investors (FII) post a net cash inflow of ₹ 871.83 Cr in Biocon Limited today, while Domestic Institutional Investors (DII) contribute a smaller cash inflow of ₹ 643.35 Cr. Together, the two groups add roughly ₹ 1.5 trillion of fresh capital to the stock on the day. The combined cash influx signals a broadly positive tone from both foreign and domestic money‑managers toward the biotech‑pharma name.
Trend vs 5‑Day Average
The day's FII cash flow stands in stark contrast to its five‑day average, which has been a net outflow of ₹ ‑894.74 Cr, indicating a sudden reversal of sentiment. Conversely, DII buying this session aligns with its five‑day average trend, which has been a consistent net purchase of ₹ +2,592.03 Cr.
F&O Positioning Data
FII participants increase their net futures‑and‑options (F&O) exposure by ₹ 643,395 Cr, suggesting a sizeable speculative or hedging stance. Their index futures positioning shows a long‑to‑short ratio of 1.2, meaning long contracts outweigh shorts by 20 percent.
Healthcare Sector Flow
Across the broader healthcare arena, recent weeks have seen FII turning net sellers while DII maintain steady buying, underscoring a sector‑wide divergence in foreign versus domestic conviction.
Market-wide FII/DII data — same for all F&O stocks. Date: 2026-10-28